Page last updated: 2024-11-02

pioglitazone and Intervertebral Disc Degeneration

pioglitazone has been researched along with Intervertebral Disc Degeneration in 1 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Intervertebral Disc Degeneration: Degenerative changes in the INTERVERTEBRAL DISC due to aging or structural damage, especially to the vertebral end-plates.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Liu, Y1
Qu, Y1
Liu, L1
Zhao, H1
Ma, H1
Si, M1
Cheng, L1
Nie, L1

Other Studies

1 other study available for pioglitazone and Intervertebral Disc Degeneration

ArticleYear
PPAR-γ agonist pioglitazone protects against IL-17 induced intervertebral disc inflammation and degeneration via suppression of NF-κB signaling pathway.
    International immunopharmacology, 2019, Volume: 72

    Topics: Adult; Aged; Anti-Inflammatory Agents; Cytokines; Female; Humans; Intervertebral Disc Degeneration;

2019